Texture analysis of [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography for predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma treated with cetuximab
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Nuclear Medicine"
DOI: 10.1007/s12149-021-01623-6
Abstract: To assess the value of the texture analysis of fluorine-18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) in predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma (POR/M-OSCC) treated with cetuximab. A total of… read more here.
Keywords: treatment response; response; treated cetuximab; texture ... See more keywords
The effect of primary tumour resection on patients with synchronous metastatic colorectal cancer treated with cetuximab‐containing regimens
Sign Up to like & getrecommendations! Published in 2022 at "ANZ Journal of Surgery"
DOI: 10.1111/ans.18117
Abstract: This study aims to assess the effect of primary tumour resection (PTR) on patients with metastatic colorectal cancer (mCRC) treated with cetuximab. read more here.
Keywords: primary tumour; metastatic colorectal; treated cetuximab; colorectal cancer ... See more keywords
Abstract 2600: Resistance biomarkers in patients with head and neck squamous cell carcinoma treated with cetuximab
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-2600
Abstract: BACKGROUND: Cetuximab, a monoclonal antibody targeting EGFR, improves overall survival in the locally advanced setting in combination with radiotherapy and in first-line recurrent setting in combination with chemotherapy in HNSCC patients. No predictive biomarker of… read more here.
Keywords: patients treated; treated cetuximab; resistance; hnscc patients ... See more keywords
Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Oncology Research"
DOI: 10.3727/096504022x16451187313084
Abstract: Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type… read more here.
Keywords: treated cetuximab; cetuximab bevacizumab; therapy; patients treated ... See more keywords